{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T17:11:27Z","timestamp":1783357887212,"version":"3.54.6"},"reference-count":29,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,11]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>In newly diagnosed multiple myeloma (NDMM), measurable residual disease (MRD) status is prognostically important, but its role in treatment decisions remains unclear. In a phase 2 trial, we assessed daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd) induction followed by a next-generation sequencing\u2013based MRD-adapted strategy. The primary outcome was complete response (CR) and stringent CR (\u2265CR) after induction. Flow cytometry was used to profile T cells. Among 39 patients, 21 (54%) achieved \u2265CR after induction (P\u00a0=\u00a0.375), with MRD-negative rates of 59% (10\u22125) and 41% (10\u22126). Patients who were MRD-negative (n\u00a0=\u00a024, group A) received lenalidomide maintenance, showing sustained MRD negativity in 14 of 18 (77.8%) for \u226512 cycles. MRD-positive transplant-eligible patients (n\u00a0=\u00a08, group B) underwent autologous stem cell transplantation, with 62.5% converting to MRD-negative at 10\u22125 (37.5% at 10\u22126) posttransplant. MRD-positive, transplant-ineligible patients (n\u00a0=\u00a04, group C) received KRd consolidation. Best MRD-negative rates improved to 77% (10\u22125) and 72% (10\u22126). No new safety concerns were identified for Dara-KRd. With a median follow-up of 30.1\u00a0months, 3, 2, and 1 patient(s) in groups A, B, and C, respectively, have progressed or died. We observed that Dara-KRd strongly activated memory T cells, which was associated with an MRD-negative state post induction. Although the primary outcome was not met, Dara-KRd induction in NDMM achieved high \u2265CR and MRD-negative rates without new safety concerns. The post induction MRD-adapted strategy deepened responses in MRD-positive patients and maintained durable MRD control in MRD-negative patients. This trial was registered at www.clinicaltrials.gov as #NCT04113018.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014417","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T21:13:01Z","timestamp":1732309981000},"page":"507-519","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9019-7438","authenticated-orcid":false,"given":"Manisha","family":"Bhutani","sequence":"first","affiliation":[{"name":"1Department of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6933-889X","authenticated-orcid":false,"given":"Myra","family":"Robinson","sequence":"additional","affiliation":[{"name":"2Department of Biostatistics and Data Sciences, Atrium Health Levine Cancer Institute, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4230-8356","authenticated-orcid":false,"given":"David","family":"Foureau","sequence":"additional","affiliation":[{"name":"3Department of Internal Medicine, Section of Hematology and Oncology, Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4547-7534","authenticated-orcid":false,"given":"Shebli","family":"Atrash","sequence":"additional","affiliation":[{"name":"1Department of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Paul","sequence":"additional","affiliation":[{"name":"1Department of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Guo","sequence":"additional","affiliation":[{"name":"3Department of Internal Medicine, Section of Hematology and Oncology, Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason M.","family":"Grayson","sequence":"additional","affiliation":[{"name":"4Department of Microbiology and Immunology, Wake Forest University School of Medicine, Winston-Salem, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5701-2174","authenticated-orcid":false,"given":"Anna","family":"Ivanina-Foureau","sequence":"additional","affiliation":[{"name":"3Department of Internal Medicine, Section of Hematology and Oncology, Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0028-3720","authenticated-orcid":false,"given":"Mauricio","family":"Pineda-Roman","sequence":"additional","affiliation":[{"name":"1Department of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Varga","sequence":"additional","affiliation":[{"name":"1Department of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0982-2345","authenticated-orcid":false,"given":"Reed","family":"Friend","sequence":"additional","affiliation":[{"name":"1Department of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Ferreri","sequence":"additional","affiliation":[{"name":"1Department of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xhevahire","family":"Begic","sequence":"additional","affiliation":[{"name":"5Clinical Trials Office, Wake Forest Baptist Comprehensive Cancer Center, Atrium Health Levine Cancer, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Norek","sequence":"additional","affiliation":[{"name":"5Clinical Trials Office, Wake Forest Baptist Comprehensive Cancer Center, Atrium Health Levine Cancer, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Drennan","sequence":"additional","affiliation":[{"name":"5Clinical Trials Office, Wake Forest Baptist Comprehensive Cancer Center, Atrium Health Levine Cancer, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle B.","family":"Anderson","sequence":"additional","affiliation":[{"name":"2Department of Biostatistics and Data Sciences, Atrium Health Levine Cancer Institute, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James T.","family":"Symanowski","sequence":"additional","affiliation":[{"name":"2Department of Biostatistics and Data Sciences, Atrium Health Levine Cancer Institute, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1661-718X","authenticated-orcid":false,"given":"Peter M.","family":"Voorhees","sequence":"additional","affiliation":[{"name":"1Department of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[{"name":"6Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,1,30]]},"reference":[{"issue":"8","key":"2025032018213028800_bib1","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"issue":"25","key":"2025032018213028800_bib2","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2025032018213028800_bib3","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","article-title":"Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial","volume":"10","author":"Voorhees","year":"2023","journal-title":"Lancet Haematol"},{"issue":"1","key":"2025032018213028800_bib4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1200\/JCO.23.01696","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma","volume":"42","author":"Leypoldt","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2025032018213028800_bib5","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1038\/s41375-023-01936-7","article-title":"Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible\/with no immediate intent for autologous stem cell transplantation","volume":"37","author":"Ocio","year":"2023","journal-title":"Leukemia"},{"issue":"4","key":"2025032018213028800_bib6","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"2025032018213028800_bib7","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A\u00a0large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"2025032018213028800_bib8","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1182\/blood.2024024371","article-title":"EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical endpoint for multiple myeloma","volume":"144","author":"Landgren","year":"2024","journal-title":"Blood"},{"issue":"6","key":"2025032018213028800_bib9","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1001\/jamaoncol.2021.0611","article-title":"Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: the MANHATTAN nonrandomized clinical trial","volume":"7","author":"Landgren","year":"2021","journal-title":"JAMA Oncol"},{"issue":"1","key":"2025032018213028800_bib10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41408-024-01045-3","article-title":"Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant","volume":"14","author":"Derman","year":"2024","journal-title":"Blood Cancer J"},{"issue":"11","key":"2025032018213028800_bib11","doi-asserted-by":"crossref","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","article-title":"Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial","volume":"10","author":"Costa","year":"2023","journal-title":"Lancet Haematol"},{"issue":"12","key":"2025032018213028800_bib12","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"8","key":"2025032018213028800_bib13","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"2025032018213028800_bib14","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/j.clml.2022.10.008","article-title":"Standardizing clinical workflow for assessing minimal residual disease by flow cytometry in multiple myeloma","volume":"23","author":"Foureau","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"2025032018213028800_bib15","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"issue":"22","key":"2025032018213028800_bib16","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1182\/blood.2020007522","article-title":"Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma","volume":"136","author":"Jasielec","year":"2020","journal-title":"Blood"},{"issue":"9","key":"2025032018213028800_bib17","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1182\/blood-2012-04-422683","article-title":"A\u00a0phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma","volume":"120","author":"Jakubowiak","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2025032018213028800_bib18","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","article-title":"Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma","volume":"1","author":"Korde","year":"2015","journal-title":"JAMA Oncol"},{"issue":"10","key":"2025032018213028800_bib19","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.clml.2021.05.017","article-title":"Daratumumab plus carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma","volume":"21","author":"Jakubowiak","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"20","key":"2025032018213028800_bib20","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1182\/blood.2023023597","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma","volume":"143","author":"Touzeau","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2025032018213028800_bib21","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1182\/blood-2018-99-119241","article-title":"Characterization of the immune impact of daratumumab by mass cytometry in multiple myeloma","volume":"132","author":"Johnson","year":"2018","journal-title":"Blood"},{"issue":"12","key":"2025032018213028800_bib22","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1038\/s43018-023-00657-1","article-title":"Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens","volume":"4","author":"Maura","year":"2023","journal-title":"Nat Cancer"},{"issue":"2","key":"2025032018213028800_bib23","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41375-020-0855-4","article-title":"Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab","volume":"35","author":"Casneuf","year":"2021","journal-title":"Leukemia"},{"issue":"7","key":"2025032018213028800_bib24","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.clml.2023.03.016","article-title":"A\u00a0clinical and correlative study of elotuzumab, carfilzomib, lenalidomide, and dexamethasone (Elo-KRd) for lenalidomide refractory multiple myeloma in first relapse","volume":"23","author":"Bhutani","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"2025032018213028800_bib25","doi-asserted-by":"crossref","first-page":"e2315989121","DOI":"10.1073\/pnas.2315989121","article-title":"CD38-RyR2 axis-mediated signaling impedes CD8+ T cell response to anti-PD1 therapy in cancer","volume":"121","author":"Kar","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2025032018213028800_bib26","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s12276-021-00576-0","article-title":"Function of \u03b3\u03b4 T cells in tumor immunology and their application to cancer therapy","volume":"53","author":"Park","year":"2021","journal-title":"Exp Mol Med"},{"issue":"suppl 1","key":"2025032018213028800_bib27","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1182\/blood-2023-187551","article-title":"Immune profiling of newly diagnosed multiple myeloma (NDMM) treated with quadruplet induction and autologous stem cell transplantation (ASCT) and comparison with achievement of minimal residual disease (MRD) negativity","volume":"142","author":"Bal","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2025032018213028800_bib28","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1182\/blood-2018-99-118088","article-title":"Increasing CD28-FOXP3+CD8+ Treg and Senescent CD8+NK2GA+Eomes+ NK-like T cells in peripheral blood of patients with multiple myeloma","volume":"132","author":"Kasakovski","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2025032018213028800_bib29","doi-asserted-by":"crossref","first-page":"104520","DOI":"10.1016\/j.ebiom.2023.104520","article-title":"Expanding scope of TEMRA in autoimmunity","volume":"90","author":"Perl","year":"2023","journal-title":"EBioMedicine"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/3\/507\/2353707\/blooda_adv-2024-014417-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/3\/507\/2353707\/blooda_adv-2024-014417-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T22:15:38Z","timestamp":1742508938000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/3\/507\/526133\/MRD-driven-phase-2-study-of-daratumumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,30]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,2,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014417","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,30]]}}}